Aligos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aligos Therapeutics (ALGS).

Price Target Range — 6 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$43Upside to Avg. PT+763.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 28, 2026	Lake Street	Daniel Brims	Initiate	Buy	$45
May 21, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$20
Mar 26, 2026	WestPark Capital	—	Initiate	Buy	$48
Mar 19, 2026	Jefferies	Anthea Li	Assumes	Buy	$60→$48
Mar 11, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$50
Jan 7, 2026	UBS	Michael Yee	Initiate	Buy	$20
Sep 12, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$50
Aug 18, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Assumes	Buy	$50
Mar 31, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$70
Mar 11, 2025	HC Wainwright & Co.	Ed Arce	PT Cut	Buy	$75→$70
Nov 7, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$75
Oct 23, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$75
Sep 20, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$75
Aug 19, 2024	HC Wainwright & Co.	Ed Arce	Initiate	Buy	$75

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.

Benzinga Newsdesk

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

WestPark Capital initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $48.

Benzinga Newsdesk

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lowers Price Target of $48.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS) with a Buy and maintains $50 price target.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

UBS analyst Michael Yee initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $20.

Benzinga Newsdesk

Aligos Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Aligos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

People Also Watch

People Also Watch

Aligos Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Aligos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PROCantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PROWestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PROJefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PROHC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PROUBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

People Also Watch

People Also Watch

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20